Predict your next investment

AGILeBiotics company logo
HEALTHCARE | Drug Development
agilebiotics.com

See what CB Insights has to offer

Stage

Seed VC | Alive

About AGILeBiotics

GILeBiotics is an early-stage pharmaceutical company focusing on the development of novel antibiotics for the treatment of multi-drug resistant infections.

AGILeBiotics Headquarter Location

De Mudden 14

Groningen, 9747 AW,

Netherlands

+31 6 39607999

Latest AGILeBiotics News

AGILeBiotics BV Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250

Aug 10, 2018

12:33 EDT 10 Aug 2018 | BioPortfolio Reports Summary AGILeBiotics BV AGILeBiotics is a pharmaceutical company with focus on the discovery and development of new antibiotics to treat multidrug resistant infections. Its patented synthetic method technology OxaSelect transforms the currently available antibiotics, which became less effective owing to bacterial resistance, into new antibiotic derivatives that surmount bacterial resistance to treat severe infections caused by multidrug resistant MDR bacteria. The company works in collaboration with The University Medical Center Groningen, The University Hospital Muenster, The Hopsital Olderburg, Integrex Research, and Syncom BV, to design and develop novel antibiotic candidates. It is a spinoff of the University of Groningen. AGILeBiotics is headquartered in Groningen, the Netherlands AGILeBiotics BV Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AGILeBiotics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AGILeBiotics is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.